Humana Inc. $HUM Holdings Cut by Clearline Capital LP

Key Points

• Clearline Capital LP significantly reduced its holdings in Humana Inc. by 48.4% during the first quarter, maintaining a total of 2,243 shares worth $593,000.
• Humana recently reported quarterly earnings of $6.27 per share, missing expectations, but its revenue increased 9.6% year-over-year to $32.39 billion.
• The company announced a quarterly dividend of $0.885 per share, with a total annualized dividend yield of 1.1%.

Clearline Capital LP lowered its holdings in Humana Inc. (NYSE:HUM - Free Report) by 48.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,243 shares of the insurance provider's stock after selling 2,102 shares during the period. Clearline Capital LP's holdings in Humana were worth $593,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC bought a new position in Humana in the first quarter worth about $1,309,000. Fred Alger Management LLC bought a new stake in shares of Humana during the fourth quarter valued at approximately $451,000. Envestnet Asset Management Inc. grew its holdings in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after buying an additional 2,950 shares in the last quarter. Circle Wealth Management LLC acquired a new stake in Humana in the 1st quarter valued at approximately $425,000. Finally, Rhumbline Advisers increased its position in Humana by 3.3% in the 1st quarter. Rhumbline Advisers now owns 246,037 shares of the insurance provider's stock valued at $65,101,000 after acquiring an additional 7,909 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

NYSE HUM opened at $307.94 on Monday. The stock has a market capitalization of $37.04 billion, a P/E ratio of 23.63, a P/E/G ratio of 1.81 and a beta of 0.44. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $369.17. The business's fifty day moving average is $261.46 and its two-hundred day moving average is $256.30. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. Humana's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, September 26th. Humana's payout ratio is presently 27.17%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HUM. Piper Sandler cut their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday, July 31st. Sanford C. Bernstein lifted their target price on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a research note on Friday. Morgan Stanley cut their target price on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Robert W. Baird dropped their target price on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Finally, Royal Bank Of Canada boosted their target price on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Seven equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $289.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.